Work

A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps7083

Authors: Ruben A. Mesa, Giovanni Barosi, Claire N. Harrison, Jean-Jacques Kiladjian, Robert Peter Gale, Abderrahmane Laadem, Torsten Gerike, Peter G. Linde, Matthew L. Sherman, Joseph Pariseau, Srdan Verstovsek

Institutions: Mays Cancer Center at UT Health San Antonio, Policlinico San Matteo Fondazione, Guy's and St Thomas' NHS Foundation Trust, Hôpital Saint-Louis, Université Paris Diderot, Celgene (United States), Acceleron Pharma (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891695269

Cites:

Cited by: 5

Related to: 10